EGFR and non-small cell lung carcinoma: A phase III clinical trial, RCHER 1050, compared dacomitinib to gefitinib in untreated patients with EGFR‐mutated NSCLC and randomly assigned patients to dacomitinib or gefitinib by a ratio of 1:1.